Study of Tislelizumab With Chemotherapy and Radiotherapy as First Treatment for Extensive Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining Tislelizumab with chemotherapy and relayed radiotherapy as a first treatment for people with extensive-stage small cell lung cancer ES-SCLC. This phase II clinical study aims to explore this combination to potentially improve outcomes in this aggressive lung cancer type. The treatment plan includes Tislelizumab given intravenously at 200 mg every three weeks along with chemotherapy drugs etoposide and either cisplatin or carboplatin for four cycles. After this induction phase, participants continue receiving Tislelizumab every three weeks as maintenance treatment for up to two years or until the disease worsens, unacceptable side effects occur, or consent is withdrawn. Radiotherapy is also given, with low-dose radiotherapy targeting lung lesions initially and stereotactic body radiotherapy focusing on main residual lesions during maintenance. Participants will be monitored regularly to assess progression-free survival, the main outcome measured from the start until disease progression or death for up to about 23 months. Other assessments include response rates, duration of response, disease control, overall survival, and tracking of treatment-related side effects. The study involves comprehensive evaluations including imaging and clinical assessments to understand how participants respond to the combined treatment over time.

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC